These observations were gathered in prostate cancer cells, in one set of which the mPGES-1 enzyme was persistently knocked-down and/or deleted (mPGES-1−/−), or pharmacologically inhibited by the specific inhibitor MF63, while in a second set, cells were transfected with a control shRNA or CRISP/Cas9 plasmid (mPGES-1+/+). This evidence concerns the gene PTGES and prostate cancer.